Vascular Biogenics terminates plans for $64.8 million IPO of stock

Underwriters cancel agreement after shareholder doesn’t pay for shares

By Devika Patel

Knoxville, Tenn., Aug. 8 – Vascular Biogenics Ltd. said its $64.8 million initial public offering of stock was terminated by the underwriters Deutsche Bank and Wells Fargo Securities, LLC due to a shareholder not paying for shares it had agreed to purchase in the offering. . The deal was announced June 6.

The biopharmaceutical company is based in Or Yehuda, Israel. It intends to list its stock on the Nasdaq under the symbol “VBLX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.